全文获取类型
收费全文 | 260068篇 |
免费 | 20131篇 |
国内免费 | 8346篇 |
专业分类
耳鼻咽喉 | 1588篇 |
儿科学 | 8204篇 |
妇产科学 | 2276篇 |
基础医学 | 22481篇 |
口腔科学 | 3837篇 |
临床医学 | 29145篇 |
内科学 | 64105篇 |
皮肤病学 | 2784篇 |
神经病学 | 28732篇 |
特种医学 | 10852篇 |
外国民族医学 | 6篇 |
外科学 | 23361篇 |
综合类 | 37290篇 |
现状与发展 | 32篇 |
一般理论 | 9篇 |
预防医学 | 18118篇 |
眼科学 | 2762篇 |
药学 | 17747篇 |
201篇 | |
中国医学 | 10842篇 |
肿瘤学 | 4173篇 |
出版年
2024年 | 252篇 |
2023年 | 4813篇 |
2022年 | 6649篇 |
2021年 | 12284篇 |
2020年 | 12271篇 |
2019年 | 9502篇 |
2018年 | 9488篇 |
2017年 | 9460篇 |
2016年 | 9816篇 |
2015年 | 9747篇 |
2014年 | 18602篇 |
2013年 | 19917篇 |
2012年 | 15250篇 |
2011年 | 16630篇 |
2010年 | 13303篇 |
2009年 | 12925篇 |
2008年 | 13004篇 |
2007年 | 12683篇 |
2006年 | 11397篇 |
2005年 | 9472篇 |
2004年 | 7942篇 |
2003年 | 6830篇 |
2002年 | 5732篇 |
2001年 | 5084篇 |
2000年 | 4137篇 |
1999年 | 3436篇 |
1998年 | 3127篇 |
1997年 | 2694篇 |
1996年 | 2333篇 |
1995年 | 2448篇 |
1994年 | 2201篇 |
1993年 | 1893篇 |
1992年 | 1776篇 |
1991年 | 1574篇 |
1990年 | 1250篇 |
1989年 | 1077篇 |
1988年 | 1022篇 |
1987年 | 910篇 |
1986年 | 784篇 |
1985年 | 922篇 |
1984年 | 771篇 |
1983年 | 453篇 |
1982年 | 577篇 |
1981年 | 475篇 |
1980年 | 363篇 |
1979年 | 326篇 |
1978年 | 247篇 |
1977年 | 212篇 |
1976年 | 172篇 |
1975年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
In clinical and epidemiological studies, there is a growing interest in studying the heterogeneity among patients based on longitudinal characteristics to identify subtypes of the study population. Compared to clustering a single longitudinal marker, simultaneously clustering multiple longitudinal markers allow additional information to be incorporated into the clustering process, which reveals co-existing longitudinal patterns and generates deeper biological insight. In the current study, we propose a Bayesian consensus clustering (BCC) model for multivariate longitudinal data. Instead of arriving at a single overall clustering, the proposed model allows each marker to follow marker-specific local clustering and these local clusterings are aggregated to find a global (consensus) clustering. To estimate the posterior distribution of model parameters, a Gibbs sampling algorithm is proposed. We apply our proposed model to the primary biliary cirrhosis study to identify patient subtypes that may be associated with their prognosis. We also perform simulation studies to compare the clustering performance between the proposed model and existing models under several scenarios. The results demonstrate that the proposed BCC model serves as a useful tool for clustering multivariate longitudinal data. 相似文献
83.
《Vaccine》2022,40(43):6201-6205
Systemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination schedule which includes an initial double dose of Fendrix in patients with IBD and compared the results with the serological responses of patients with IBD who received the standard schedule. Seroprotection rates were 86.2 % and 88.9 % in the modified and standard schedule groups respectively. One-third of patients obtained seroprotection after only one double dose vaccine. A double dose may be considered in patients with IBD at high short-term risk of HBV infection when a rapid protective response is warranted. 相似文献
84.
川崎病(Kawasaki disease,KD)是一种急性自身免疫性系统性血管炎,是发达国家儿童获得性心脏病的主要病因。KD最严重的后果是冠状动脉病变(coronary artery lesions,CALs),与KD的预后相关。临床研究证实静脉注射丙种球蛋白(IVIG)耐药是CALs的独立危险因素。近年来,一系列的预测模型已被开发来评估IVIG耐药的风险。然而,目前基于KD儿童人口学特征、临床表现、实验室检查及遗传特性的IVIG耐药性预测评分系统在不同民族和同一民族不同地区的人群中存在显著差异,尚未建立适用普遍人群的预测模型。 相似文献
85.
86.
《Saudi Dental Journal》2022,34(7):596-603
ObjectiveStudies have shown that gingival crevices may be a significant route for SARS-CoV-2 entry. However, the role of oral health in the acquisition and severity of COVID-19 is not known.DesignA retrospective analysis was performed using electronic health record data from a large urban academic medical center between 12/1/2019 and 8/24/2020. A total of 387 COVID-19 positive cases were identified and matched 1:1 by age, sex, and race to 387 controls without COVID-19 diagnoses. Demographics, number of missing teeth and alveolar crestal height were determined from radiographs and medical/dental charts. In a subgroup of 107 cases and controls, we also examined the rate of change in alveolar crestal height. A conditional logistic regression model was utilized to assess association between alveolar crestal height and missing teeth with COVID-19 status and with hospitalization status among COVID-19 cases.ResultsIncreased alveolar bone loss, OR = 4.302 (2.510 – 7.376), fewer missing teeth, OR = 0.897 (0.835–0.965) and lack of smoking history distinguished COVID-19 cases from controls. After adjusting for time between examinations, cases with COVID-19 had greater alveolar bone loss compared to controls (0.641 ± 0.613 mm vs 0.260 ± 0.631 mm, p < 0.01.) Among cases with COVID-19, increased number of missing teeth OR = 2.1871 (1.146– 4.174) was significantly associated with hospitalization.ConclusionsAlveolar bone loss and missing teeth are positively associated with the acquisition and severity of COVID-19 disease, respectively. 相似文献
87.
88.
89.
90.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献